Immune Oncology Research Institute
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Immune Oncology Research Institute sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Immune Oncology Research Institute: 1 sponsored US clinical trial, 1 recruiting.
Immune Oncology Research Institute sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with 1 trials.
Mid-pack sponsor footprint
Immune Oncology Research Institute is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Therapeutic Areas
What is open in the Immune Oncology Research Institute pipeline
1 recruiting of 1 indexed (100% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Immune Oncology Research Institute: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Immune Oncology Research Institute sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Immune Oncology Research Institute page
1 registered trials is a research-attention snapshot, not an endorsement of Immune Oncology Research Institute or any single study.
- 1 of Immune Oncology Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is the condition Immune Oncology Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Immune Oncology Research Institute pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.